Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 8, 2020
Daily News
April 8, 2020
- World’s 1st Topical JAK Inhibitor Corectim, AbbVie’s Rinvoq, Bayer’s Nubeqa OK’ed for Listing on April 22
April 8, 2020
- Roche Diagnostics Launches Coronavirus Test in Japan
April 8, 2020
- Japan Ethical Drug Sales Up 0.1% in February: Crecon
April 8, 2020
- Novartis Japan Chided over Flawed Zolgensma Data, Delayed Responses
April 8, 2020
- EFPIA Japan Says No Drug Shortages for Now, but Warns of Fluid Situation
April 8, 2020
- Japan Books 13.9 Billion Yen to Boost Avigan Stockpile, Abe Vows to Expand Access to Fujifilm Drug
April 8, 2020
- JPMA to Vet Impact of Drug Pricing Reform, Make Proposals for R&D Tax Break System: FY2020 Project Plan
April 8, 2020
- Takeda’s NSCLC Med Alunbrig Bags EU Nod for 1st-Line Use
April 8, 2020
- Daiichi Sankyo Sets Up Task Force to Develop COVID-19 Vaccine, Treatment
April 8, 2020
- Kyowa Pharma Joins Forces with German neuroCare Group in CNS
April 8, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…